Tesamorelin and HGH Together: What Is Known
Tesamorelin and HGH taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 7 results, 2 Oct 2026).
Side by side
Showing 9 of 12 fields where the two differ. Category, PCAC vote, Jul 2026, Evidence strength are the same or both unknown.
| Field | Tesamorelin | HGH |
|---|---|---|
| Class | GHRH analog | Recombinant growth hormone |
| Also called | tesa, Egrifta | GH, growth hormone, generic HGH, IU |
| Category | Growth hormone | Growth hormone |
| FDA status | FDA approved (Egrifta) | FDA approved (prescription only) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption. | Prohibited by WADA (S2.2.3)Growth hormone and its analogues and fragments are prohibited at all times (S2.2.3). |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | 11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR) | 0.4 hours IV; 3.0 hours subcutaneousintravenous (normal adults); subcutaneous (GHD adults), Genotropin · FDA label (Genotropin) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101 | Human RCT evidence, 4 of 4Strongest: Journal of applied physiology 2014, PMID 24235105 |
| Human studies we summarised | 12 human (11 randomized or controlled) of 16 summarised | 13 human (13 randomized or controlled) of 20 summarised |
| Typical study doses |
|
|
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026) | Not in the letters we track |
Tesamorelin vs HGH
Choosing between the two rather than combining them? The comparison lines them up field by field.
One acts upstream of GH, the other is GH
Tesamorelin's randomized HIV trial measured visceral adipose tissue, which fell 15.2% on tesamorelin and rose 5.0% on placebo; athletic outcomes were not measured.[14]
The tesamorelin label states it is not indicated for weight loss management as it has a weight neutral effect.[5]
A systematic review of randomized trials in healthy, physically fit young people found lean body mass rose on growth hormone, but strength and exercise capacity did not seem to improve.[16]
Where the labels overlap on cancer
Tesamorelin is contraindicated with active malignancy and in pregnancy, and also with hypothalamic-pituitary axis disruption.[5]
Genotropin's label tells prescribers to monitor patients with preexisting tumours for progression or recurrence.[9]
Glucose warning on the tesamorelin label
The tesamorelin label warns that glucose intolerance or diabetes may develop and that glucose should be evaluated before and during therapy.[5]
Given together?
The dataset search for tesamorelin with GH therapy returned 7 PubMed records, and none is classed as a study of the pair.
Calculated from pubmed query (somatropin[tiab] OR "recombinant human growth hormone"[tiab] OR "recombinant growth hormone"[tiab] OR rhGH[tiab] OR "growth hormone therapy"[tiab] OR "growth hormone treatment"[tiab] OR "growth hormone replacement"[tiab] OR "growth hormone administration"[tiab] OR "GH therapy"[tiab] OR "GH treatment"[tiab] OR "GH replacement"[tiab] OR "GH administration"[tiab] OR "growth hormone injection"[tiab] OR "growth hormone injections"[tiab] OR "growth hormone supplementation"[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]); search date 2026-10-02; records returned 7; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key hgh__tesamorelin); no arithmetic applied.
WADA's growth hormone-releasing hormone clause names tesamorelin among the GHRH analogues.[2]
WADA lists growth hormone itself, with its analogues and fragments, under S2.2.3.[2]
Common questions
HGH vs tesamorelin: which has trial data for visceral fat?
Tesamorelin does: in the HIV trial, visceral adipose tissue fell in the tesamorelin group while it rose in placebo.[14]
Can tesamorelin be combined with HGH?
No study of the combination was classed as relevant. The tesamorelin label contraindicates use with active malignancy, and the Genotropin label advises monitoring patients with preexisting tumors.[5]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 5EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 7Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 8The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
- 9GENOTROPIN (SOMATROPIN) KIT [PFIZER LABORATORIES DIV PFIZER INC]FDA label (Genotropin), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 10Effect of growth hormone on aging connective tissue in muscle and tendon: gene expression, morphology, and function following immobilization and rehabilitation.Journal of applied physiology (Bethesda, Md. : 1985) · 2014PMID 24235105Accessed 2 Oct 2026
- 11Impact of GH replacement therapy on sleep in adult patients with GH deficiency of pituitary origin.European journal of endocrinology · 2013PMID 23447518Accessed 2 Oct 2026
- 12Local administration of growth hormone stimulates tendon collagen synthesis in elderly men.Journal of applied physiology (Bethesda, Md. : 1985) · 2012PMID 22961272Accessed 2 Oct 2026
- 13PubMed search: (somatropin[tiab] OR "recombinant human growth hormone"[tiab] OR "recombinant growth hormone"[tiab] OR rhGH[tiab] OR "growth hormone therapy"[tiab] OR "growth hormone treatment"[tiab] OR "growth hormone replacement"[tiab] OR "growth hormone administration"[tiab] OR "GH therapy"[tiab] OR "GH treatment"[tiab] OR "GH replacement"[tiab] OR "GH administration"[tiab] OR "growth hormone injection"[tiab] OR "growth hormone injections"[tiab] OR "growth hormone supplementation"[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 15Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes.The Journal of clinical endocrinology and metabolism · 2005PMID 15784718Accessed 2 Oct 2026
- 16Systematic review: the effects of growth hormone on athletic performance.Annals of internal medicine · 2008PMID 18347346Accessed 2 Oct 2026
Found an error? Report a correction.